0 CHECKOUT

Anal Cancer - Pipeline Review, H2 2015

  • ID: 3440623
  • September 2015
  • 68 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advaxis, Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • ISA Pharmaceuticals B.V.
  • MedImmune, LLC
  • Novartis AG
  • MORE

Anal Cancer - Pipeline Review, H2 2015

Summary

The report ‘Anal Cancer - Pipeline Review, H2 2015’, provides an overview of the Anal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advaxis, Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • ISA Pharmaceuticals B.V.
  • MedImmune, LLC
  • Novartis AG
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Anal Cancer Overview

Therapeutics Development

Pipeline Products for Anal Cancer - Overview

Pipeline Products for Anal Cancer - Comparative Analysis

Anal Cancer - Therapeutics under Development by Companies

Anal Cancer - Therapeutics under Investigation by Universities/Institutes

Anal Cancer - Pipeline Products Glance

Clinical Stage Products

Anal Cancer - Products under Development by Companies

Anal Cancer - Products under Investigation by Universities/Institutes

Anal Cancer - Companies Involved in Therapeutics Development

Advaxis, Inc.

Amgen Inc.

Eli Lilly and Company

ISA Pharmaceuticals B.V.

MedImmune, LLC

Novartis AG

Sun Pharma Advanced Research Company Ltd.

Anal Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

axalimogene filolisbac - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for HPV Associated Cancers - Drug Profile

Product Description

Mechanism of Action

R&D Progress

durvalumab + tremelimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ISA-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

paclitaxel albumin free - Drug Profile

Product Description

Mechanism of Action

R&D Progress

panitumumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PDR-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

prexasertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Anal Cancer - Recent Pipeline Updates

Anal Cancer - Dormant Projects

Anal Cancer - Product Development Milestones

Featured News & Press Releases

Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer

Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience

Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV

Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV

Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy

Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anal Cancer, H2 2015

Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Anal Cancer - Pipeline by Advaxis, Inc., H2 2015

Anal Cancer - Pipeline by Amgen Inc., H2 2015

Anal Cancer - Pipeline by Eli Lilly and Company, H2 2015

Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2015

Anal Cancer - Pipeline by MedImmune, LLC, H2 2015

Anal Cancer - Pipeline by Novartis AG, H2 2015

Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Anal Cancer Therapeutics - Recent Pipeline Updates, H2 2015

Anal Cancer - Dormant Projects, H2 2015

List of Figures

Number of Products under Development for Anal Cancer, H2 2015

Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Advaxis, Inc.
Amgen Inc.
Eli Lilly and Company
ISA Pharmaceuticals B.V.
MedImmune, LLC
Novartis AG
Sun Pharma Advanced Research Company Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)